
Key specifications and handling guidance.
Everything you need to know before starting.
MK-677, commonly known as ibutamoren or ibutamoren mesylate, is a non-peptide growth hormone secretagogue that has been investigated in scientific research for its activity at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.
The compound appears in scientific literature under several closely related research names, including MK-677, MK677, MK-0677, ibutamoren, and L-163,191. These terms are associated with the same extensively studied research compound.
Interest in MK-677 research has focused primarily on its interaction with the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) pathways. Clinical and experimental studies have examined these pathways in relation to endocrine function, body-composition markers, metabolism, sleep physiology, bone turnover, and age-related changes.
MK-677 is an orally active, non-peptide growth hormone secretagogue originally developed during research into compounds capable of stimulating endogenous growth hormone secretion.
Its mechanism differs from compounds that act directly on androgen receptors. Although MK-677 is frequently mentioned alongside selective androgen receptor modulators in online discussions, MK-677 is not a SARM.
Instead, ibutamoren acts as an agonist of the GHS-R1a receptor, the receptor also activated by the naturally occurring hormone ghrelin. This receptor is involved in the regulation of growth hormone secretion and several related physiological processes.
This distinction is important when interpreting MK-677 research because findings involving ibutamoren should not automatically be applied to SARMs or other classes of research compounds.
Scientific research indicates that ibutamoren interacts with GHS-R1a receptors involved in the regulation of endogenous growth hormone secretion.
Growth hormone is normally released in pulses rather than at a constant rate. Controlled human studies have investigated whether MK-677 influences this natural pulsatile secretion pattern and how these changes affect downstream markers such as IGF-1 and IGF-binding proteins.
Research in healthy older adults found that administration of MK-677 increased measures of pulsatile growth hormone secretion and serum IGF-1. Other controlled studies have similarly documented changes in the GH/IGF-1 axis across different research populations.
These findings explain why the relationship between MK-677, growth hormone, IGF-1, and ghrelin receptor signaling remains one of the primary areas of scientific interest surrounding ibutamoren.
Body composition has also been evaluated in controlled MK-677 research.
A randomized, placebo-controlled study involving healthy older adults examined changes in fat-free mass, body fat, strength, metabolic markers, and physical function over an extended research period. Researchers observed an increase in fat-free mass in the MK-677 group compared with placebo.
Importantly, the increase in fat-free mass did not translate into significant improvements in strength or physical function in that study. Total fat mass and abdominal visceral fat also did not demonstrate the reductions that might be assumed from changes in growth hormone signaling alone.
These findings are important because they illustrate why changes in laboratory or body-composition measurements should not automatically be interpreted as demonstrated improvements in athletic performance or clinical outcomes.
The metabolic effects of ibutamoren are another significant area of research.
Some controlled human studies have reported changes in glucose regulation during MK-677 exposure. In a long-term study of healthy older adults, fasting blood glucose increased and insulin sensitivity decreased in the MK-677 group.
A separate study involving obese adult subjects also reported impairment in glucose homeostasis during research with MK-677 despite increases in growth hormone, IGF-1 and fat-free mass.
These findings demonstrate that research into ibutamoren involves more than the GH/IGF-1 pathway alone and that metabolic variables are important when interpreting scientific results.
Researchers have also investigated the relationship between MK-677 and sleep physiology.
A small double-blind, placebo-controlled study evaluated sleep architecture in healthy younger and older adults. Changes were observed in specific stages of sleep, including REM and deep sleep measurements.
Because the study involved a relatively small number of participants, these findings should be interpreted in the context of the study design rather than generalized into claims about sleep treatment or clinical effectiveness.
The research nevertheless contributed to scientific interest in the relationship between ghrelin-receptor signaling, growth hormone secretion, circadian physiology and sleep.
Ibutamoren has also been studied in relation to bone turnover and bone-related biomarkers.
Clinical research involving older adults reported changes in biochemical markers associated with bone formation and resorption alongside increases in IGF-1.
Changes in bone-turnover markers, however, are not equivalent to proving improvements in bone density, fracture prevention or clinical bone health. Longer-term outcomes and the population being studied are important when interpreting these findings.
This distinction is particularly relevant when reviewing research summaries that may present biological markers as though they represent established clinical benefits.
Published research supports the conclusion that MK-677 can interact with the ghrelin receptor pathway and influence growth hormone and IGF-1 signaling under controlled research conditions.
Researchers have investigated associated changes involving:
However, outcomes have varied depending on the population, study duration and endpoint being measured.
For example, increased fat-free mass has not consistently translated into increased strength or improved physical function. Some studies have also identified metabolic changes and adverse effects that are important when evaluating the overall research literature.
For this reason, MK-677 research should be interpreted from the complete scientific evidence rather than from individual biomarkers or isolated study findings.
Yes. MK-677 and ibutamoren refer to the same research compound.
Scientific databases and published literature may also use the designation MK-0677 or the development code L-163,191. Ibutamoren mesylate refers to the mesylate salt form of the compound.
As a result, scientific searches for MK677, MK-677, MK-0677, ibutamoren, or ibutamoren mesylate may return research relating to the same underlying compound.
Researchers looking for information about MK-677 in Canada should distinguish scientific research involving ibutamoren from its regulatory status.
Health Canada currently identifies ibutamoren (MK-677) as not authorized in Canada for any use. It should therefore not be represented as an authorized medication or approved health product in Canada.
Regulatory status can change independently from the existence of published research. Researchers should consult current Health Canada information and other appropriate regulatory sources when evaluating investigational compounds.
MK-677 has been investigated in human clinical studies as well as preclinical research, but the existence of human studies does not by itself establish a compound as safe, effective or approved for general use.
Research populations have included older adults, individuals with particular medical conditions and other specifically selected groups. Results obtained in one population should not automatically be generalized to healthy individuals, athletes or other populations.
Reported findings have included increases in appetite, changes in glucose regulation, reductions in insulin sensitivity, fluid retention or edema, and muscle discomfort in some studies. A study involving older adults recovering from hip fracture was terminated early following a safety signal involving congestive heart failure in that specific patient population.
These findings reinforce the importance of reviewing both potential biological effects and study limitations when evaluating MK-677 literature.
Researchers interested in the scientific history of MK-677 can review peer-reviewed publications including:
Patchett AA et al.
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.
Proceedings of the National Academy of Sciences, 1995.
PMID: 7624358
Chapman IM et al.
Stimulation of the growth hormone–insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects.
Journal of Clinical Endocrinology & Metabolism, 1996.
PMID: 8954023
Copinschi G et al.
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Neuroendocrinology, 1997.
PMID: 9349662
Svensson J et al. / MK-677 Study Group research
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults.
Journal of Bone and Mineral Research, 1999.
PMID: 10404019
Nass R et al.
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Annals of Internal Medicine, 2008.
PMID: 18981485
MK-677 remains an investigational research compound. Information presented on this page summarizes characteristics of ibutamoren and areas examined in published scientific literature and should not be interpreted as evidence of an approved therapeutic, medical, bodybuilding or performance-enhancing use.
LRG Labs MK-677 is offered for research purposes only and is not intended for human consumption or medical use.
Complete your stack with complementary picks.